Atricure, Inc. (ATRC) Stock Price & Analysis
Atricure, Inc. (ATRC) rose 6.18% to USD 35.04 as of July 25, 2026 at 04:49 UTC, according to Nexqual real-time market data.
ATRC last closed at USD 33; the session ranged USD 32.41–35.34 on volume of 1,654,801 shares. Market capitalization is $1.77B, with a 52-week range of USD 25.36–43.18 (NGM). Source: Nexqual, July 25, 2026 at 04:49 UTC.
Key Statistics (as of July 25, 2026 at 04:49 UTC)
| Price | USD 35.04 |
|---|---|
| Change | ▲ 6.18% (up) |
| Previous Close | USD 33 |
| Open | USD 34.04 |
| Day Range | USD 32.41 – 35.34 |
| 52-Week Range | USD 25.36 – 43.18 |
| Volume | 1,654,801 shares |
| Market Cap | $1.77B |
| Exchange | NGM |
Technical Analysis (ATRC)
Nexqual's technical model rates ATRC "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 04:49 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 64.56 (neutral) |
| vs SMA50 | Above (USD 29.93) |
| MACD | 1.42 (positive) |
Analyst Ratings (ATRC)
Wall Street analysts rate ATRC "Buy" based on 8 analysts, with a mean price target of USD 47 (range USD 36–55), per Nexqual as of July 25, 2026 at 04:49 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 47 |
| High Target | USD 55 |
| Low Target | USD 36 |
| Buy / Hold / Sell | 7 / 2 / 0 |
Earnings (ATRC)
| Next Earnings Date | 2026-07-23 |
|---|---|
| EPS Estimate | USD 0.01 |
| Revenue Estimate | $151.09M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.18 vs est 0.02 ▲ beat |
| 2026-03-31 | USD 0 vs est -0.06 ▲ beat |
| 2025-12-31 | USD 0.06 vs est -0.04 ▲ beat |
| 2025-09-30 | USD -0.01 vs est -0.12 ▲ beat |
Source: Nexqual, July 25, 2026 at 04:49 UTC.
Financials & Fundamentals (ATRC)
| Total Revenue | $569.62M |
|---|---|
| Revenue Growth (YoY) | +12.80% |
| Gross Margin | +76.30% |
| Operating Margin | +6.29% |
| Profit Margin | +1.85% |
| ROE | +2.15% |
| Debt / Equity | 13.76 |
| Current Ratio | 4.22 |
| Total Cash | $167.79M |
| Total Debt | $71.05M |
Source: Nexqual, July 25, 2026 at 04:49 UTC.
Financial Health Score (ATRC)
Nexqual rates Atricure, Inc.'s overall financial health "Solid" across five dimensions, as of July 25, 2026 at 04:49 UTC.
| Growth | Solid — Revenue +15% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 76%, operating 6% |
| Balance Sheet | Strong — $168M cash vs $71M debt, net cash position |
| Cash Flow | Mixed — No data |
| Efficiency | Weak — ROE 2%, ROA 1.3% |
Ownership (ATRC)
| Insider Ownership | +3.86% |
|---|---|
| Institutional Ownership | +102.26% |
| Shares Outstanding | 50.64M |
| Float | 46.66M |
| Short % of Float | +10.00% |
Source: Nexqual, July 25, 2026 at 04:49 UTC.
Leadership (ATRC)
Atricure, Inc. is led by Michael H. Carrel (age 54), CEO, President & Director, per Nexqual as of July 25, 2026 at 04:49 UTC.
| CEO, President & Director | Michael H. Carrel (age 54) |
|---|---|
| Chief Financial Officer | Angela L. Wirick (age 47) |
| Chief Operating Officer | Douglas J. Seith (age 59) |
| Chief Marketing & Strategy Officer | Justin J. Noznesky (age 47) |
| Chief Scientific Officer | Vinayak Doraiswamy (age 52) |
Major Backers & Investors (ATRC)
Notable institutional backers of Atricure, Inc. include Wellington Management, Alliancebernstein L.P., Hood River Capital Management LLC, according to Nexqual as of July 25, 2026 at 04:49 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Wellington Management | 6.68% |
| Alliancebernstein L.P. | 6.44% |
| Hood River Capital Management LLC | 6.16% |
| Nomura Asset Management International Inc | 3.56% |
| Goldman Sachs | 3.29% |
| Manager Directed Portfolios-Hood River Small-Cap Growth Fund | 3.02% |
| Delaware Group Equity Funds V-Nomura Small Cap Core Fund | 2.93% |
| Marshall Wace LLP | 2.9% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 17.05% |
| BlackRock | 10.27% |
Source: Nexqual, July 25, 2026 at 04:49 UTC.
From Atricure, Inc.'s Latest SEC 10-K Filing (filed 2026-02-19)
Key Strengths & Strategy (as disclosed to the SEC)
- AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally.
- It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation.
- In addition, the company sells various reusable cardiac surgery instruments.
- It markets and sells its products through independent distributors and direct sales personnel.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ANGO | AngioDynamics, Inc. | USD 13.59 | ▼ 1.66% |
| CNMD | CONMED Corporation | USD 42.68 | ▲ 1.62% |
| LMAT | LeMaitre Vascular, Inc. | USD 95.59 | ▼ 3.26% |
| ATEC | Alphatec Holdings, Inc. | USD 8.26 | ▲ 2.48% |
| AXGN | AxoGen, Inc. | USD 39.49 | ▲ 0.3% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 04:49 UTC. This page is informational and not investment advice.